D Gomez1, P B Patel1, C Lacasia-Purroy2, C Byrne1, R P Sturgess3, D Palmer4, S Fenwick1, G J Poston1, H Z Malik5. 1. North Western Hepatobiliary Unit, Aintree University Hospital NHS Foundation Trust, Longmoor Lane, Liverpool L3 4FG, UK. 2. Department of Anaesthesia, Aintree University Hospital NHS Foundation Trust, Liverpool, UK. 3. Department of Gastroenterology, Aintree University Hospital NHS Foundation Trust, Liverpool, UK. 4. Department of Oncology, Aintree University Hospital NHS Foundation Trust, Liverpool, UK. 5. North Western Hepatobiliary Unit, Aintree University Hospital NHS Foundation Trust, Longmoor Lane, Liverpool L3 4FG, UK. Electronic address: Hassan.Malik@aintree.nhs.uk.
Abstract
AIMS: To assess the outcomes of patients with hilar cholangiocarcinoma following referral to a specialist multi-disciplinary team. METHODS: Over an 11-year period, patients referred with hilar cholangiocarcinoma were identified from a prospectively maintained registry. Collated data included demographics, operative findings and histo-pathological data. Survival differences and prognostic factors were determined. RESULTS: 345 patients were referred with hilar cholangiocarcinoma, of which 57 (16.5%) patients had surgery. Prior to 2008, of 143 patients referred, only 17 (11.9%) patients underwent surgery, compared to 40 (19.8%) of 202 patients referred from 2008 onwards (p = 0.051). In the surgery group, the majority of patients underwent left hemi-hepatectomy (n = 19). In addition, portal vein (n = 5), hepatic artery (n = 2) and inferior vena cava (n = 3) resections were performed. The R0 resection rate was 73.7%. The morbidity and mortality rates were 59.6% and 14.0%, respectively. The median disease-free survival was 16 (4-101) months. The presence of lymph node metastasis (p = 0.002) was the only predictor of poorer disease-free survival. The 5-year overall survival was 39.5% and was significantly better than that of the palliative group (p < 0.001). CONCLUSIONS: Surgery is the optimal treatment option for patients with hilar cholangiocarcinoma and is associated with better overall survival. Prompt referral to tertiary centres with a core team of clinicians to manage this difficult condition may allow more patients to come to potentially curative surgical resections.
AIMS: To assess the outcomes of patients with hilar cholangiocarcinoma following referral to a specialist multi-disciplinary team. METHODS: Over an 11-year period, patients referred with hilar cholangiocarcinoma were identified from a prospectively maintained registry. Collated data included demographics, operative findings and histo-pathological data. Survival differences and prognostic factors were determined. RESULTS: 345 patients were referred with hilar cholangiocarcinoma, of which 57 (16.5%) patients had surgery. Prior to 2008, of 143 patients referred, only 17 (11.9%) patients underwent surgery, compared to 40 (19.8%) of 202 patients referred from 2008 onwards (p = 0.051). In the surgery group, the majority of patients underwent left hemi-hepatectomy (n = 19). In addition, portal vein (n = 5), hepatic artery (n = 2) and inferior vena cava (n = 3) resections were performed. The R0 resection rate was 73.7%. The morbidity and mortality rates were 59.6% and 14.0%, respectively. The median disease-free survival was 16 (4-101) months. The presence of lymph node metastasis (p = 0.002) was the only predictor of poorer disease-free survival. The 5-year overall survival was 39.5% and was significantly better than that of the palliative group (p < 0.001). CONCLUSIONS: Surgery is the optimal treatment option for patients with hilar cholangiocarcinoma and is associated with better overall survival. Prompt referral to tertiary centres with a core team of clinicians to manage this difficult condition may allow more patients to come to potentially curative surgical resections.
Authors: Robert J S Coelen; Jimme K Wiggers; Chung Y Nio; Marc G Besselink; Olivier R C Busch; Dirk J Gouma; Thomas M van Gulik Journal: HPB (Oxford) Date: 2015-02-28 Impact factor: 3.647
Authors: Hendrik T J Mantel; Andrie C Westerkamp; René Adam; William F Bennet; Daniel Seehofer; Utz Settmacher; Francisco Sánchez-Bueno; Joan Fabregat Prous; Emmanuel Boleslawski; Styrbjörn Friman; Robert J Porte Journal: PLoS One Date: 2016-06-08 Impact factor: 3.240
Authors: Robert J S Coelen; Anthony T Ruys; Marc G H Besselink; Olivier R C Busch; Thomas M van Gulik Journal: Surg Endosc Date: 2016-02-19 Impact factor: 4.584
Authors: Robert J S Coelen; Anthony T Ruys; Jimme K Wiggers; Chung Y Nio; Joanne Verheij; Dirk J Gouma; Marc G H Besselink; Olivier R C Busch; Thomas M van Gulik Journal: Ann Surg Oncol Date: 2016-09-01 Impact factor: 5.344
Authors: Leonard M Quinn; Declan F J Dunne; Robert P Jones; Graeme J Poston; Hassan Z Malik; Stephen W Fenwick Journal: Eur Surg Date: 2018-05-04 Impact factor: 0.953